
A new request for information asks for comments on dose selection, safety monitoring, eligibility criteria, and oversight approaches to support the responsible development of ibogaine drug products.
StudyManager
announced the release of Reveal 3.2, with enhanced features that provide greater ease of use and performance for research sites, academic medical centers, and hospitals.Reveal 3.2 provides a host of enhanced features focused on greater ease of use and performance including:






